Novartis AG (NVS)
142.57USD -2.15% (-3.14)
Over 5Y: +105.7%
Style
Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.
Financials Annual
Figures
A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.
Novartis AG reported revenue of 54.5B USD for the year ending 31 December 2025, up 8.4% from 50.3B a year earlier. Every figure, period by period ›
How it scores
For a valuation multiple, the low end is the good end.
Quality
How much of the revenue is really kept — and what did it take to earn it?
19 of 19 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.
Valuation
What does the price ask for what the company earns, owns and pays out?
11 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.
Durability
How predictable is the revenue, and how much of it is already committed?
3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.
Resilience
Can the balance sheet absorb a bad year?
11 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.
Growth
Is the business getting bigger, and is it getting more profitable?
12 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.